Andrew C. Phillips PhD

Dr. Phillips earned his Ph.D. from the University of Glasgow, performed postdoctoral studies and the NCI and was an Assistant Professor at the Medical College of Georgia prior to joining Abbott/Abbvie. At Abbvie Dr. Phillips has been involved in multiple ADC programs including a number that has entered clinical development. These include depatuximab mafadotin, Abbvie’s first ADC, where he served as the lead biologist and ABBV-155, Abbvie’s first-in-class BCL-XL inhibitor ADC for which he served as Project Director. Dr. Phillips current role is as Director, Next Generation Antibody Drug Conjugates.